<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01339091</url>
  </required_header>
  <id_info>
    <org_study_id>DUR001-301</org_study_id>
    <nct_id>NCT01339091</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regiment (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Durata Therapeutics Inc., an affiliate of Allergan plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Durata Therapeutics Inc., an affiliate of Allergan plc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy)
      of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral
      linezolid) for the treatment of patients with a suspected or proven gram-positive bacterial
      skin or skin structure infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early Clinical Efficacy</measure>
    <time_frame>48-72 hours after the initiation of study therapy</time_frame>
    <description>Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size and temperature</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>&gt;= 20% Reduction in Lesion Area</measure>
    <time_frame>48-72 hours after the initiation of study therapy</time_frame>
    <description>Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Status</measure>
    <time_frame>End of Treatment Visit (Day 14-15)</time_frame>
    <description>Compare the clinical efficacy at end of treatment visit of dalbavancin to the comparator regimen based on lesion size, local signs, temperature and receipt of non-study antibiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Status</measure>
    <time_frame>Follow-Up Visit (day 28)</time_frame>
    <description>Compare the clinical efficacy at the day 28 follow-up visit of dalbavancin to the comparator regimen based on lesion size, local signs, temperature and receipt of non-study antibiotics</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">573</enrollment>
  <condition>Abscess</condition>
  <condition>Wound Infection</condition>
  <condition>Surgical Site Infection</condition>
  <condition>Cellulitis</condition>
  <arm_group>
    <arm_group_label>Dalbavancin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin with possible switch to oral linezolid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalbavancin</intervention_name>
    <description>IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8</description>
    <arm_group_label>Dalbavancin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin / Linezolid</intervention_name>
    <description>IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.</description>
    <arm_group_label>Vancomycin with possible switch to oral linezolid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients 18 - 85 years of age.

          2. Signed and dated informed consent document.

          3. Major abscess, surgical site infection, traumatic wound infection or cellulitis
             suspected or confirmed to be caused by Gram-positive bacteria.

          4. At least two (2) local signs and symptoms of ABSSSI and at least one (1) systemic sign
             of infection.

          5. Requires a minimum of 3 days of IV therapy.

          6. Patient willing and able to comply with study procedures.

        Exclusion Criteria:

        Patients presenting with any of the following:

          1. A contra-indication to any required study drug.

          2. Pregnant or nursing females.

          3. Sustained shock.

          4. Participation in another study of an investigational drug or device within 30 days.

          5. Receipt of a systemically or topically administered antibiotic within 14 days prior to
             randomization, except receipt of a single dose of a short-acting antibacterial drug 3
             or more days prior to randomization.

          6. Infection due to a dalbavancin or vancomycin-resistant organism.

          7. Evidence of meningitis, necrotizing fasciitis, gas gangrene, gangrene, septic
             arthritis, osteomyelitis, and/or endovascular infection.

          8. Exclusively gram-negative bacterial or a fungal ABSSSI.

          9. Venous catheter infection.

         10. Infection of a diabetic foot ulcer or a decubitus ulcer.

         11. Device-related infections.

         12. Gram-negative bacteremia.

         13. Infected burns.

         14. Infected limb with critical ischemia.

         15. Superficial/simple skin and skin structure infections.

         16. Concomitant condition requiring non-study antibacterial therapy.

         17. ABSSSI requiring therapy for longer than 14 days.

         18. Adjunctive therapy with hyperbaric oxygen.

         19. More than 2 surgical interventions for ABSSSI anticipated.

         20. Chronic inflammatory condition precluding assessment of clinical response.

         21. Absolute neutrophil count &lt; 500 cells/mm3.

         22. Human immunodeficiency virus (HIV) infection with a CD4 cell count &lt; 200 cells/mm3.

         23. Recent bone marrow transplant, &gt; 20 mg prednisolone per day (or equivalent) or
             receiving immunosuppressant drugs after organ transplantation.

         24. Regular, chronic antipyretic use in patients unable to modify during the first three
             days of study drug therapy.

         25. Life expectancy less than 3 months.

         26. Conditions that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results.

         27. Prior participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Dunne, MD</last_name>
    <role>Study Director</role>
    <affiliation>Durata Therapeutics Inc., an affiliate of Allergan plc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <zip>91702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>90706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <zip>90620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Carmel</city>
        <state>California</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>92911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32837</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>St. Cloud</city>
        <state>Florida</state>
        <zip>34769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Pocatello</city>
        <state>Idaho</state>
        <zip>83202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Moline</city>
        <state>Illinois</state>
        <zip>61265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Rock Island</city>
        <state>Illinois</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Clinical Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Opelousas</city>
        <state>Louisiana</state>
        <zip>70570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Lima</city>
        <state>Ohio</state>
        <zip>45801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Middleton</city>
        <state>Wisconsin</state>
        <zip>53562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0J9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <zip>G9A 1Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Dubrovnik</city>
        <zip>2000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Clinical Site</name>
      <address>
        <city>Slavonski Brod</city>
        <zip>35000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Zagreb</city>
        <zip>1000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Clinical Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Legionowo</city>
        <zip>05-120</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Warszawa</city>
        <zip>03-401</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Kharkiv</city>
        <state>Ukraine</state>
        <zip>61037</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Kyiv city</city>
        <state>Ukraine</state>
        <zip>02125</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Moscow</city>
        <zip>111020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Clinical Site</name>
      <address>
        <city>Moscow</city>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Moscow</city>
        <zip>129327</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Perm</city>
        <zip>614036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Saratov</city>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>192242</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Clinical Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>94354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634064</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Cherkasy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Kyiv</city>
        <zip>02125</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69032</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durata Study Site</name>
      <address>
        <city>Zhytomyr</city>
        <zip>10002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2011</study_first_submitted>
  <study_first_submitted_qc>April 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2011</study_first_posted>
  <results_first_submitted>November 7, 2013</results_first_submitted>
  <results_first_submitted_qc>November 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 25, 2013</results_first_posted>
  <last_update_submitted>December 26, 2013</last_update_submitted>
  <last_update_submitted_qc>December 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Cellulitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Dalbavancin</mesh_term>
    <mesh_term>Teicoplanin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dalbavancin</title>
          <description>Dalbavancin : IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8</description>
        </group>
        <group group_id="P2">
          <title>Vancomycin +/- Oral Linezolid</title>
          <description>Vancomycin : IV Vancomycin (dosed per standard of care) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="288"/>
                <participants group_id="P2" count="285"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="284"/>
                <participants group_id="P2" count="284"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="261"/>
                <participants group_id="P2" count="257"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dalbavancin</title>
          <description>Dalbavancin : IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8</description>
        </group>
        <group group_id="B2">
          <title>Vancomycin +/- Oral Linezolid</title>
          <description>Vancomycin : IV Vancomycin (dosed per standard of care) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="288"/>
            <count group_id="B2" value="285"/>
            <count group_id="B3" value="573"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.8" spread="15.3"/>
                    <measurement group_id="B2" value="48.9" spread="15.08"/>
                    <measurement group_id="B3" value="48.9" spread="15.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Early Clinical Efficacy</title>
        <description>Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size and temperature</description>
        <time_frame>48-72 hours after the initiation of study therapy</time_frame>
        <population>The ITT population consisted of all randomly assigned patients regardless of whether or not they received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Dalbavancin</title>
            <description>Dalbavancin : IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin +/- Oral Linezolid</title>
            <description>Vancomycin : IV Vancomycin (dosed per standard of care) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Early Clinical Efficacy</title>
          <description>Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size and temperature</description>
          <population>The ITT population consisted of all randomly assigned patients regardless of whether or not they received study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="285"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240"/>
                    <measurement group_id="O2" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Non-Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority hypothesis test is a one-sided hypothesis test performed at the 2.5% level of significance. If the lower limit of the 95% CI for the difference in response rates in the ITT population is greater than -10% the NI of dalbavancin to vancomycin/linezolid will be concluded.</non_inferiority_desc>
            <param_type>Difference in Proportions</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>7.9</ci_upper_limit>
            <estimate_desc>Confidence intervals were adjusted for fever at baseline</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>&gt;= 20% Reduction in Lesion Area</title>
        <description>Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size</description>
        <time_frame>48-72 hours after the initiation of study therapy</time_frame>
        <population>The ITT population consisted of all randomly assigned patients regardless of whether or not they received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Dalbavancin</title>
            <description>Dalbavancin : IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin +/- Oral Linezolid</title>
            <description>Vancomycin : IV Vancomycin (dosed per standard of care) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>&gt;= 20% Reduction in Lesion Area</title>
          <description>Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size</description>
          <population>The ITT population consisted of all randomly assigned patients regardless of whether or not they received study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="285"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259"/>
                    <measurement group_id="O2" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Non-Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Status</title>
        <description>Compare the clinical efficacy at end of treatment visit of dalbavancin to the comparator regimen based on lesion size, local signs, temperature and receipt of non-study antibiotics</description>
        <time_frame>End of Treatment Visit (Day 14-15)</time_frame>
        <population>Clinical Evaluable Population based on certain inclusion/exclusion criteria, length of study therapy, concomitant antibacterials, concomitant surgical procedure and non-missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Dalbavancin</title>
            <description>Dalbavancin : IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin +/- Oral Linezolid</title>
            <description>Vancomycin : IV Vancomycin (dosed per standard of care) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Status</title>
          <description>Compare the clinical efficacy at end of treatment visit of dalbavancin to the comparator regimen based on lesion size, local signs, temperature and receipt of non-study antibiotics</description>
          <population>Clinical Evaluable Population based on certain inclusion/exclusion criteria, length of study therapy, concomitant antibacterials, concomitant surgical procedure and non-missing data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214"/>
                    <measurement group_id="O2" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Status</title>
        <description>Compare the clinical efficacy at the day 28 follow-up visit of dalbavancin to the comparator regimen based on lesion size, local signs, temperature and receipt of non-study antibiotics</description>
        <time_frame>Follow-Up Visit (day 28)</time_frame>
        <population>Clinical Evaluable Population based on certain inclusion/exclusion criteria, length of study therapy, concomitant antibacterials, concomitant surgical procedure and non-missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Dalbavancin</title>
            <description>Dalbavancin : IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin +/- Oral Linezolid</title>
            <description>Vancomycin : IV Vancomycin (dosed per standard of care) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Status</title>
          <description>Compare the clinical efficacy at the day 28 follow-up visit of dalbavancin to the comparator regimen based on lesion size, local signs, temperature and receipt of non-study antibiotics</description>
          <population>Clinical Evaluable Population based on certain inclusion/exclusion criteria, length of study therapy, concomitant antibacterials, concomitant surgical procedure and non-missing data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                    <measurement group_id="O2" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Begins from the time that the patient provides informed consent through the last follow up visit, Day 70. Any SAE occurring any time after the reporting period must be promptly reported if a causal relationship to investigational product is suspected.</time_frame>
      <desc>Adverse events were analyzed in the safety population which is defined as all patients in the ITT population who received at least 1 dose of dalbavancin or vancomycin (active) study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dalbavancin</title>
          <description>Dalbavancin : IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8</description>
        </group>
        <group group_id="E2">
          <title>Vancomycin +/- Oral Linezolid</title>
          <description>Vancomycin : IV Vancomycin (dosed per standard of care) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Embolic pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI will provide Durata an opportunity to review any proposed publication or other type of disclosure at least 30 days before they are submitted. If any patent action is required to protect intellectual property rights, the Investigator agrees to delay the disclosure for a period not to exceed an additional 60 days. If the study is part of a multi-center study, the Investigator agrees that the first publication is to be a joint publication covering all centers.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Zelasky</name_or_title>
      <organization>Durata Therapeutics</organization>
      <phone>203-871-4616</phone>
      <email>mzelasky@duratatherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

